OCCIDENT
Venture capitalMunich · Pre-Seed–Series A · 4 people tracked
Investment thesis
OCCIDENT invests in deep-tech startups that transfer promising scientific findings into concrete applications, financing spin-offs from research whose innovations address societal challenges and create value. The firm invests its own capital, takes a long-term view focused on sustainable success potential, and supports portfolio companies financially and with entrepreneurial experience. Its focus areas include life sciences and biotechnology as well as industrial tech. Positioning itself as 'The Science Investor,' OCCIDENT emphasizes an entrepreneurial mindset in portfolio management, from deal sourcing and due diligence through closing and active support, aiming to bring innovations to market success 'the OCCIDENT way.'
Source: firm website, verified Jul 30, 2026.
Team · 4 people
from the firm's websiteCo-founder who leads investment management, guiding investment cases through closing, defining terms and shaping portfolio management. Studied economics in Vienna with controlling experience at international corporations and a long track record as a venture capital investor.
Co-founder who leads OCCIDENT, sets company strategy and oversees investment decisions as well as finance, HR and marketing. Studied economics in Vienna and has marketing experience at international corporations plus a background as a real estate and venture capital investor.
Leads the life sciences team, sourcing deals, running due diligence and managing the portfolio. Studied pharmacy and economics in Zurich with extensive private equity and venture capital experience.
Focuses on disruptive innovation in life sciences and biotechnology, responsible for deal sourcing, due diligence and portfolio building. Holds a management master's from TU Munich and a chemistry degree from Linz, with prior work as an innovation consultant and at a fintech startup.
Investments · 2 tracked
founders shown can be your intro pathBiotech company that raised a CHF 2.4M pre-seed round with OCCIDENT participation.
Life sciences company developing antibody-drug conjugates (ADCs); raised over EUR 300M Series C and was acquired by Gilead.
Frequently asked questions
- What stage does OCCIDENT invest at?
- OCCIDENT invests at the Pre-Seed, Seed, Series A stages.
- What sectors does OCCIDENT focus on?
- OCCIDENT focuses on Advanced Manufacturing, Biotech, Deep Tech, Hardware, Healthtech.
- Where is OCCIDENT located?
- OCCIDENT is headquartered in Munich, DE.
Similar investors
Hyderabad Angels is an angel investor network headquartered in Hyderabad, India, backing early-stage founders across India since 2010.
Lux Capital is a venture capital firm investing in emerging science and technology companies.
SOSV is a deep tech venture capital firm that backs founders building startups in areas like human and planetary health, biology, decarbonization of heavy industry, and physics/chemistry-based technologies. It operates programs including HAX and has offices in San Francisco and New York.
China Growth Capital (Huachuang Capital / 华创资本) is an early-stage investor focused on frontier technology and life sciences, having invested in over 200 companies since launching its fund in 2014.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.